Pyridazinone Myosin Inhibition for Muscular Dystrophy Breakdown Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Individuals with neuromuscular conditions such as Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and Limb-girdle muscular dystrophies experience excessive muscle breakdown and inflammation due to muscle contractions, leading to muscle weakness and functional decline, with existing treatments either failing to reduce breakdown or causing muscle weakness.
Innovation Solution
Administering a compound of Formula (I) as a muscle fast myosin (Type II) inhibitor at doses ranging from 1 mg to 40 mg per day to selectively inhibit fast-twitch muscle fibers, reducing muscle contractions while preserving muscle strength and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a compound is administered to reduce skeletal muscle contractions in neuromuscular conditions, then muscle breakdown is reduced, but muscle strength and physical abilities deteriorate
Solution Approach 1:
The patent applies local quality by developing a selective inhibitor that specifically targets fast-twitch muscle fibers (Type II) while sparing slow-twitch fibers (Type I). This selective inhibition allows reduction of muscle breakdown in fast-twitch fibers without significantly impacting overall muscle strength and function, thereby resolving the contradiction between reducing harmful muscle breakdown and preserving muscle strength.
Solution Approach 2:
The patent utilizes parameter changes by modulating the inhibition of myosin ATPase activity in fast-twitch fibers. By controlling the degree and duration of inhibition, the compound reduces muscle breakdown while maintaining sufficient muscle contraction capability for strength and physical abilities, thus resolving the contradiction between reducing muscle breakdown and preserving muscle strength.
2Object-affected harmful factors
If skeletal muscle contractions are reduced to treat neuromuscular conditions, then muscle breakdown decreases, but physical function and quality of life deteriorate
Solution Approach 1:
The selective inhibition of fast-twitch fibers while preserving slow-twitch fiber function allows maintenance of physical function and quality of life. Slow-twitch fibers continue to provide sustained contraction for daily activities, while fast-twitch fiber breakdown is reduced, thus resolving the contradiction between reducing muscle breakdown and maintaining physical function.
Solution Approach 2:
The patent applies partial action by inhibiting only a portion of muscle fibers (fast-twitch Type II) rather than all muscle fibers. This partial inhibition reduces muscle breakdown while leaving sufficient muscle contraction capability intact to maintain physical function and quality of life, avoiding excessive reduction that would impair productivity.
3Object-affected harmful factors
If existing treatments are used to reduce muscle breakdown, then muscle breakdown decreases, but the treatments fail to preserve or improve muscle strength
Solution Approach 1:
The patent resolves this contradiction by implementing local quality through selective inhibition of fast-twitch fibers. This targeted approach reduces muscle breakdown in the specific fiber type responsible for excessive contraction while preserving strength in slow-twitch fibers and overall muscle mass, unlike non-selective treatments that compromise muscle strength.
Data Source
AI summary
Treatments of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), and McArdle's disease, with compositions comprising substituted pyridazinone compounds are described herein.